Ionis (IONS) Q1 2026 earnings review
Massive Olezarsen Upgrade Overshadows Near-Term TRYNGOLZA Volatility
Ionis delivered an optically strong Q1 with revenue surging 87% YoY to $246 million, though this was heavily subsidized by $95 million in R&D milestone payments. The underlying commercial narrative is a tale of two launches: DAWNZERA is accelerating rapidly, doubling sequentially, while the lead asset TRYNGOLZA saw sales slashed nearly in half vs Q4 2025 as the company intentionally navigates aggressive payer negotiations. However, the market will likely look straight past this near-term compression. Management successfully secured FDA Priority Review for olezarsen in sHTG and massively increased its peak sales target from $2B to $3B, signaling extreme confidence in its blockbuster status. Driven by early DAWNZERA success and milestone cash, Ionis confidently raised both its FY26 revenue and operating loss guidance.
🐂 Bull Case
Olezarsen's sNDA for sHTG was accepted for FDA Priority Review (PDUFA June 30, 2026), and peak sales estimates were hiked by 50% to over $3 billion. This transforms Ionis's growth trajectory.
The HAE launch is gaining immediate traction. DAWNZERA net sales hit $16M in Q1, accelerating 125% sequentially from Q4 2025, proving Ionis's commercial engine can penetrate competitive switch markets.
🐻 Bear Case
Q1 TRYNGOLZA sales collapsed to $27M from $50M in 25Q4. Management previously warned of a 'meaningful decline' due to payer negotiations ahead of the sHTG launch, highlighting the severe margin/price compression required to access broader markets.
Total royalty revenue fell to $58M from $64M a year ago. SPINRAZA royalties decelerated (-8% YoY), forcing the company to rely heavily on its new commercial launches and lumpy milestone payments to hit top-line targets.
⚖️ Verdict: 🟢
Bullish. While the TRYNGOLZA sequential drop is a stark reminder of the costs of market expansion, the $3B peak sales upgrade for sHTG and the successful Priority Review are foundational shifts in the company's valuation thesis. The R&D engine continues to easily fund the commercial transition.
Key Themes
Olezarsen sHTG Expansion Upgraded to >$3B
The central value driver for Ionis just got significantly larger. Management increased the peak sales guidance for olezarsen in severe hypertriglyceridemia (sHTG) from >$2B to >$3B, reflecting higher confidence in market penetration and the drug's differentiated clinical profile (85% reduction in acute pancreatitis events). Securing an FDA Priority Review with a June 30, 2026 PDUFA date accelerates this timeline.
TRYNGOLZA Sales Reversing Ahead of Label Expansion
A major data point contradicting the 'continued commercial success' narrative: TRYNGOLZA sales plummeted sequentially from $50M in 25Q4 to $27M in 26Q1. This was driven by a 'decrease in net price.' While management warned in Q4 2025 that payer talks ahead of the sHTG launch would compress revenue, this 46% QoQ drop exposes the brutal reality of transitioning a drug from an ultra-rare (FCS) to a broad (sHTG) pricing model.
DAWNZERA Launch Accelerating
The prophylactic HAE treatment DAWNZERA is rapidly gaining ground, with sales accelerating to $16M in Q1 (+125% vs Q4 2025). The introduction of a new $110-$120M FY26 guidance bracket for the drug implies strong, sustained momentum in a highly competitive market where ~20% of patients switch therapies annually.
R&D Engine Continues to Subsidize Operations
Ionis booked $138M in R&D revenue in Q1, heavily supported by $95M in clinical and regulatory milestone payments from multiple partnerships. This non-dilutive capital is critical as the company funds expensive commercial launches for TRYNGOLZA, DAWNZERA, and soon, zilganersen.
Macro Pressures & Tariffs
Management had previously flagged the rapidly evolving macro environment, particularly referencing new tariff policies and FDA changes. While no catastrophic impact has hit yet, the company maintains a complex global supply chain across South Korea, Europe, and the U.S., which requires monitoring for margin pressure.
Zilganersen Data Execution Risk
Zilganersen's NDA for Alexander disease was accepted for Priority Review (PDUFA Sept 22, 2026). While positive, management previously noted a 'higher degree of uncertainty' regarding adoption because it is the first disease-modifying therapy in this indication, meaning the company will have to build the market from scratch.
Other KPIs
Accelerating from $278M in Q1 2025. The 31% YoY increase was driven entirely by SG&A ($151M, up ~100% YoY), reflecting aggressive commercial build-outs for DAWNZERA, TRYNGOLZA, and pre-launch activities for zilganersen and the broader olezarsen sHTG expansion. R&D costs remained stable.
Decreased from $2.68B at the end of FY25. The bulk of this drop is directly attributable to the deliberate $633 million maturity payout of 0% convertible notes due April 1, 2026. The balance sheet remains highly fortified to support cash-flow breakeven targets by 2028.
Decelerating. Down 9% YoY from $64M in Q1 2025. SPINRAZA royalties slipped to $44M (from $48M a year prior), and 'Other royalties' fell to $3M from $7M. WAINUA royalties provided a small offset, growing to $11M from $9M.
Guidance
Accelerating vs the company's prior FY26 guidance ($800-$825M). When factoring out the one-time $280M upfront payment from FY25 (which inflated FY25 revenue to $944M), this implies a robust ~33% YoY underlying growth rate driven by commercial sales and milestone achievements.
Decelerating. This new specific guidance bracket implies flat YoY performance compared to the $108M generated in FY25. Given the drug exited 25Q4 at a $50M quarterly run rate, this guidance cements the severe net price compression happening as the company shifts from the FCS indication to the sHTG indication.
Accelerating. With $16M already booked in Q1, the midpoint ($115M) implies quarterly sales must average ~$33M for the rest of the year. This requires continuous quarter-over-quarter growth and aggressive market share capture from existing prophylactic HAE therapies.
Improving. Management lowered the projected loss from the prior $500-$550M range, flowing the $75M revenue guidance beat directly through to the bottom line. This underscores strong financial discipline and keeps the company on track for its 2028 cash-flow breakeven target.
Key Questions
TRYNGOLZA Pricing Floor
With TRYNGOLZA net sales dropping from $50M in Q4 to $27M in Q1, what is the exact pricing floor we should expect as you secure broad payer access for the sHTG population? Is the $100-$110M FY26 guidance purely a reflection of price compression, or is there also volume attrition?
DAWNZERA Switch Dynamics
DAWNZERA requires a steep ramp to hit the $110-$120M guidance. Are you primarily capturing the 20% of HAE patients who naturally switch each year, or are you actively expanding the prophylactic market among treatment-naive patients?
Peak Sales Assumptions for sHTG
You've increased the peak sales estimate for olezarsen from >$2B to >$3B. What specific metric drove this upgrade—was it better-than-expected payer reception to the acute pancreatitis data, or an expansion in your assumed addressable patient population?
Capital Allocation Post-Convertible Paydown
Having cleared the $633M convertible debt hurdle, how does this alter your capital allocation strategy heading into the back half of 2026, specifically regarding BD vs internal neurology pipeline acceleration?